| Code | CSB-RA004935MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to TMB-365, targeting the CD4 glycoprotein. CD4 is a transmembrane protein predominantly expressed on the surface of T helper cells, regulatory T cells, monocytes, macrophages, and dendritic cells. As a co-receptor for the T cell receptor (TCR), CD4 plays a critical role in adaptive immunity by facilitating MHC class II-restricted antigen recognition and T cell activation. CD4+ T cells are central to immune response coordination, and their dysfunction or depletion is associated with autoimmune diseases, immunodeficiency disorders including HIV/AIDS, transplant rejection, and various inflammatory conditions.
TMB-365 is an established research antibody widely used for investigating CD4-mediated immune processes and T cell biology. This biosimilar provides researchers with a reliable tool for studying T cell differentiation, immune regulation, and disease mechanisms involving CD4+ cell populations. It supports investigations into immunological disorders, infectious disease pathogenesis, and therapeutic development targeting immune modulation. The antibody enables consistent experimental results in diverse immunology research applications.
There are currently no reviews for this product.